Boehringer Ingelheim EU grants marketing authorisation for Giotrif® for the treatment of patients with advanced squamous cell carcinoma (SqCC) of the lung

Published 7, April 2016 at 132 × 172 in Boehringer Ingelheim: EU grants marketing authorisation for Giotrif® for the treatment of patients with advanced squamous cell carcinoma (SqCC) of the lung

Dr. Mehdi Shahidi, Medical Head, Solid Tumour Oncology, Boehringer Ingelheim

Dr. Mehdi Shahidi, Medical Head, Solid Tumour Oncology, Boehringer Ingelheim

Bookmark the permalink.

Comments are closed.